Hepatology

• 

  Publication Venue For

  • Access to Technology to Support Telehealth in Areas without Specialty Care for Liver Disease. 2022
  • Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study..  75:1471-1479. 2022
  • Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle..  75:782-784. 2022
  • Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. 2022
  • Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention. 2022
  • Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome. 2022
  • A revised electronic version of RUCAM for the diagnosis of DILI. 2022
  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study..  74:2952-2964. 2021
  • Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis..  74:3127-3145. 2021
  • Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health..  74:2808-2812. 2021
  • AASLD Deepens Commitment to Diversity, Equity, and Inclusion..  74:2216-2225. 2021
  • Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art..  74:2233-2240. 2021
  • Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows..  74:2226-2232. 2021
  • Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease..  74:1220-1233. 2021
  • A Beautiful Day in the Neighborhood: Application of Single-Cell Transcriptomics to Unravel Liver Cell Heterogeneity in Diseased Human Livers..  74:547-549. 2021
  • HLA-B*35:01 and Green Tea-Induced Liver Injury..  73:2484-2493. 2021
  • Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management..  73:1985-2004. 2021
  • A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis..  73:1105-1116. 2021
  • Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates..  73:1132-1139. 2021
  • Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations..  73:1199-1206. 2021
  • Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action..  73:811-820. 2021
  • Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH..  73:625-643. 2021
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies..  73:821-832. 2021
  • Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury..  73:268-281. 2021
  • Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases..  73:318-365. 2021
  • Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?.  73:414-421. 2021
  • Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria..  72:2014-2028. 2020
  • Reply..  72:2241-2242. 2020
  • Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH..  72:1219-1229. 2020
  • Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus..  72:569-583. 2020
  • Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?.  72:770-771. 2020
  • Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial..  72:58-71. 2020
  • A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection..  71:1894-1909. 2020
  • Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma..  71:1967-1987. 2020
  • NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis..  71:1198-1212. 2020
  • Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B..  71:539-548. 2020
  • The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials..  70:1913-1927. 2019
  • A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation..  70:1816-1829. 2019
  • Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum..  70:1841-1855. 2019
  • Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps..  70:1457-1469. 2019
  • The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis..  70:788-801. 2019
  • A Roadmap for Value-Based Payment Models Among Patients With Cirrhosis..  69:1300-1305. 2019
  • Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease..  69:684-698. 2019
  • "Too Female" for Liver Transplantation..  68:2424-2425. 2018
  • Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis..  68:1646-1648. 2018
  • Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report..  68:1653-1655. 2018
  • Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies..  67:1797-1806. 2018
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial..  67:549-559. 2018
  • Comments on cochrane review on direct-acting antivirals for hepatitis C..  66:1016-1019. 2017
  • Death and liver transplantation within 2 years of onset of drug-induced liver injury..  66:1275-1285. 2017
  • Drug rechallenge following drug-induced liver injury..  66:646-654. 2017
  • Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis..  65:1543-1556. 2017
  • Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements..  65:1267-1277. 2017
  • The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study..  64:2077-2088. 2016
  • Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression..  64:999-1000. 2016
  • Reply..  64:994-995. 2016
  • A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease..  64:85-91. 2016
  • Reply..  63:1057-1058. 2016
  • The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota..  63:764-775. 2016
  • Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data..  63:437-444. 2016
  • Liver receptor homolog-1 is a critical determinant of methyl-pool metabolism..  63:95-106. 2016
  • Benzyl Alcohol: A novel treatment for acetaminophen overdose?.  62:1641-1642. 2015
  • Diabetes and prediabetes in patients with hepatitis B residing in North America..  62:1364-1374. 2015
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus..  62:932-954. 2015
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C..  62:409-416. 2015
  • Reply: To PMID 24849310..  61:1770-1771. 2015
  • Prometheus and progenitors..  61:1427-1429. 2015
  • Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients..  61:790-801. 2015
  • Reply: To PMID 24123276..  61:1094. 2015
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development..  61:843-856. 2015
  • Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation..  61:285-291. 2015
  • Patatin-like phospholipase domain-containing protein 3 and liver disease: opportunities to unravel mechanisms underlying statistical associations..  61:18-20. 2015
  • Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity..  61:98-107. 2015
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC..  60:1461-1462. 2014
  • Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network..  60:1399-1408. 2014
  • Reply: To PMID 23913408..  60:1445-1446. 2014
  • The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice..  60:1023-1034. 2014
  • Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network..  60:679-686. 2014
  • Trends in hepatitis C treatment uptake in the United States..  60:768-769. 2014
  • Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes..  60:158-168. 2014
  • Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver..  59:2065-2067. 2014
  • Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice..  59:1366-1380. 2014
  • Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study..  59:1311-1319. 2014
  • Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease..  59:471-482. 2014
  • Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations..  59:661-670. 2014
  • Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice..  58:1801-1813. 2013
  • Identification of driver genes in hepatocellular carcinoma by exome sequencing..  58:1693-1702. 2013
  • Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome..  58:1514-1515. 2013
  • HINT2 and fatty liver disease: mitochondrial protein hyperacetylation gives a hint?.  57:1681-1683. 2013
  • Hedgehog pathway and pediatric nonalcoholic fatty liver disease..  57:1814-1825. 2013
  • Successful transplantation of human hepatic stem cells with restricted localization to liver using hyaluronan grafts..  57:775-784. 2013
  • Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis..  57:708-715. 2013
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection..  56:2071-2081. 2012
  • Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations..  56:1730-1740. 2012
  • Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?.  56:1352-1360. 2012
  • Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study..  56:1311-1318. 2012
  • Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes..  56:952-960. 2012
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response..  56:444-454. 2012
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner..  56:49-56. 2012
  • Lost in translation? IL28B's discovery and the journey back to the patient..  56:5-8. 2012
  • Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease..  55:1711-1721. 2012
  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association..  55:2005-2023. 2012
  • After goodbye? Dead hepatocytes as a biomarker for fibrosis and steatohepatitis..  55:333-335. 2012
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response..  54:1538-1546. 2011
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication..  54:1580-1590. 2011
  • Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?.  54:1454-1462. 2011
  • Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era..  54:1313-1321. 2011
  • The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury..  54:931-939. 2011
  • Racial differences in hepatitis C treatment eligibility..  54:70-78. 2011
  • High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients..  53:1809-1818. 2011
  • Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia..  53:1246-1258. 2011
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR..  53:389-395. 2011
  • Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model..  53:483-492. 2011
  • Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds..  53:293-305. 2011
  • Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis..  53:106-115. 2011
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype..  52:2243-2244. 2010
  • IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C..  52:1888-1896. 2010
  • Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review..  52:2216-2222. 2010
  • Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma..  52:1690-1701. 2010
  • Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates..  52:1443-1454. 2010
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C..  52:1208-1215. 2010
  • Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease..  52:913-924. 2010
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection..  52:822-832. 2010
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy..  52:864-874. 2010
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis..  52:612-622. 2010
  • Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells..  52:278-290. 2010
  • Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease..  51:1998-2007. 2010
  • Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease..  51:1961-1971. 2010
  • Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection..  51:1904-1911. 2010
  • Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice..  51:1712-1723. 2010
  • Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway..  51:535-544. 2010
  • Epithelial-to-mesenchymal transitions in the liver..  50:2007-2013. 2009
  • Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis..  50:1421-1430. 2009
  • Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?.  50:1314. 2009
  • Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production..  50:518-527. 2009
  • Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network..  49:1904-1912. 2009
  • Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States..  49:1563-1570. 2009
  • Liver biopsy..  49:1017-1044. 2009
  • Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network..  49:809-820. 2009
  • Hepatitis B virus viral load and treatment decision..  49:699. 2009
  • Recruitment of host progenitor cells in rat liver transplants..  49:587-597. 2009
  • Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins..  48:1799-1809. 2008
  • Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis..  48:1149-1156. 2008
  • Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells..  47:958-965. 2008
  • Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis..  47:625-635. 2008
  • Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus..  46:1341-1349. 2007
  • Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. 2022
  • Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. 2018
  • Hedgehog regulates yes-associated protein 1 in regenerating mouse liver. 2016
  • To transfuse or not to transfuse in upper gastrointestinal hemorrhage? That is the question. 2014
  • Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. 2014